HUE066360T2 - Eravaciklin kristályformái - Google Patents

Eravaciklin kristályformái

Info

Publication number
HUE066360T2
HUE066360T2 HUE17794505A HUE17794505A HUE066360T2 HU E066360 T2 HUE066360 T2 HU E066360T2 HU E17794505 A HUE17794505 A HU E17794505A HU E17794505 A HUE17794505 A HU E17794505A HU E066360 T2 HUE066360 T2 HU E066360T2
Authority
HU
Hungary
Prior art keywords
eravacycline
crystalline forms
crystalline
forms
Prior art date
Application number
HUE17794505A
Other languages
English (en)
Inventor
Danny Lafrance
Philip Hogan
Yansheng Liu
Minsheng He
Chi-Li Chen
John Niu
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Publication of HUE066360T2 publication Critical patent/HUE066360T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE17794505A 2016-10-19 2017-10-19 Eravaciklin kristályformái HUE066360T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410230P 2016-10-19 2016-10-19

Publications (1)

Publication Number Publication Date
HUE066360T2 true HUE066360T2 (hu) 2024-07-28

Family

ID=60263035

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17794505A HUE066360T2 (hu) 2016-10-19 2017-10-19 Eravaciklin kristályformái

Country Status (15)

Country Link
US (3) US10961190B2 (hu)
EP (1) EP3529236B1 (hu)
JP (2) JP7492335B2 (hu)
KR (2) KR102660864B1 (hu)
CN (2) CN110582486B (hu)
DK (1) DK3529236T3 (hu)
ES (1) ES2978198T3 (hu)
HR (1) HRP20240605T1 (hu)
HU (1) HUE066360T2 (hu)
MA (1) MA46567A (hu)
PH (1) PH12019500822A1 (hu)
PL (1) PL3529236T3 (hu)
SG (1) SG11201903327PA (hu)
SI (1) SI3529236T1 (hu)
WO (1) WO2018075767A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03329B (me) 2012-08-31 2019-10-20 Tetraphase Pharmaceuticals Inc Jedinjenja tetraciklina
PT3390358T (pt) 2016-01-22 2020-11-09 Sandoz Ag Bis-cloridrato de eravaciclina cristalino
EP3529236B1 (en) 2016-10-19 2024-02-07 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
AU2023278510A1 (en) * 2022-05-29 2024-12-19 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Eravacycline for treating cancer
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
DE122006000058I2 (de) 1991-10-04 2007-09-13 Wyeth Corp 7-Substituierte-9-substituierte Amino-6-Demethyl-6-Deoxy-Tetracycline
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5834450A (en) 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
WO1999037307A1 (en) 1998-01-23 1999-07-29 Trustees Of Tufts College Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
EP1124558A4 (en) 1998-09-28 2004-10-27 Res Foundation Ofstate Univers NEW INHIBITANT AGAINST CATARACT EDUCATION
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001098260A1 (en) 2000-06-16 2001-12-27 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
EA006170B1 (ru) 2000-07-07 2005-10-27 Трастис Оф Тафтс Коллидж Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния субъекта
PT1301467E (pt) 2000-07-07 2006-12-29 Tufts College Compostos de minociclina 9-substituídos
EP2166000A1 (en) 2000-07-07 2010-03-24 Trustees Of Tufts College 7-, 8- and 9-substituted tetracycline compounds
AU2001271619B2 (en) 2001-03-13 2008-05-15 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
CA2440757A1 (en) 2001-03-14 2002-09-19 Michael Draper Substituted tetracycline compounds as synergistic antifungal agents
JP2004530661A (ja) 2001-03-14 2004-10-07 パラテック ファーマシューティカルズ インコーポレイテッド 抗真菌剤としての置換テトラサイクリン化合物
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20040092490A1 (en) 2001-04-24 2004-05-13 Michael Draper Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
EP2311798A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
CA2479877C (en) 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
WO2004038001A2 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2298322A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2005082860A1 (en) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
US7807842B2 (en) 2004-05-21 2010-10-05 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2284152A3 (en) 2004-10-25 2011-10-05 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2005299294B2 (en) 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
EP1848686A2 (en) 2005-02-15 2007-10-31 Wyeth 9-substituted tetracyclines
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
EP1991236A2 (en) 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CA2648668C (en) 2006-04-07 2015-06-23 The President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
AU2007249695A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
EP2076133B1 (en) 2006-10-11 2012-12-12 President and Fellows of Harvard College Synthesis of enone intermediate
SI2109602T1 (sl) 2006-12-21 2014-06-30 Paratek Pharmaceuticals, Inc. Derivati tetraciklina za zdravljenje bakterijskih, virusnih in parazitskih infekcij
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
PT2176216E (pt) 2007-07-06 2012-07-27 Paratek Pharm Innc Métodos de síntese de minociclina substituída na posição 9
WO2009032326A1 (en) 2007-09-07 2009-03-12 Dr. Reddy's Laboratories Ltd. New tetracycline derivatives as antiinfective agents
WO2009128913A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2010006292A1 (en) 2008-07-11 2010-01-14 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
EP2323972B1 (en) 2008-08-08 2013-07-03 Tetraphase Pharmaceuticals, Inc. C7-fluoro substituted tetracycline compounds
EP2424834B1 (en) 2009-04-30 2018-07-11 President and Fellows of Harvard College Synthesis of tetracyclines and intermediates thereof
WO2010129055A1 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
EP2427425B1 (en) 2009-05-08 2017-03-08 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
CA2772386C (en) 2009-08-28 2017-09-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CN102821769A (zh) 2010-03-10 2012-12-12 大学健康网络 替加环素用于治疗癌症的用途
AU2011235176B2 (en) 2010-03-31 2015-05-14 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
WO2012021712A1 (en) 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Tetracycline analogs
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
PT2707003T (pt) * 2011-05-12 2019-08-05 Paratek Pharm Innc Sais cristalinos da amida do ácido (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetra-hidroxi-7-[(metoxi(metil)amino]-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octa-hidro-naftaceno-2-carboxílico e métodos de utilização dos mesmos
ME03329B (me) 2012-08-31 2019-10-20 Tetraphase Pharmaceuticals Inc Jedinjenja tetraciklina
MA40836A (fr) 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
WO2017097891A1 (en) * 2015-12-10 2017-06-15 Sandoz Ag Crystalline eravacycline
PT3390358T (pt) 2016-01-22 2020-11-09 Sandoz Ag Bis-cloridrato de eravaciclina cristalino
CA3034891A1 (en) 2016-08-30 2018-03-08 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds and methods of treatment
EP3529236B1 (en) 2016-10-19 2024-02-07 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline

Also Published As

Publication number Publication date
ES2978198T3 (es) 2024-09-06
WO2018075767A1 (en) 2018-04-26
SG11201903327PA (en) 2019-05-30
CN110582486A (zh) 2019-12-17
JP2022186979A (ja) 2022-12-15
HRP20240605T1 (hr) 2024-07-19
DK3529236T3 (da) 2024-05-13
KR20190065414A (ko) 2019-06-11
KR20240058958A (ko) 2024-05-07
US20190256462A1 (en) 2019-08-22
EP3529236A1 (en) 2019-08-28
EP3529236B1 (en) 2024-02-07
KR102660864B1 (ko) 2024-04-25
PL3529236T4 (pl) 2024-07-08
CN117903083A (zh) 2024-04-19
SI3529236T1 (sl) 2024-08-30
PH12019500822A1 (en) 2019-08-19
US20230416212A1 (en) 2023-12-28
MA46567A (fr) 2019-08-28
JP2019531321A (ja) 2019-10-31
US20210363103A1 (en) 2021-11-25
PL3529236T3 (pl) 2024-07-08
JP7492335B2 (ja) 2024-05-29
CN110582486B (zh) 2024-01-12
US10961190B2 (en) 2021-03-30
US11578044B2 (en) 2023-02-14

Similar Documents

Publication Publication Date Title
EP3136857A4 (en) Crystalline form of baricitinib
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
IL246385A0 (en) Crystalline forms of efitinib di-malate
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
ZA201706282B (en) Solid forms of menaquinols
PL3529236T3 (pl) Krystaliczne formy erawacykliny
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL253479A0 (en) Crystalline forms of efinconazole
IL269792B (en) Crystalline forms of (s)–apoxolner
IL265445A (en) crystalline forms
GB201419174D0 (en) Crystalline forms
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
HK1255148A1 (zh) 結晶形式
IL270937A (en) Crystalline forms of saltalicib
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form